The panel recommended against blanket access to Pfizer boosters for those 16 and older, but urged offering them to those 65 and older and “at high risk,” a term that offers the White House some room to expand access.
source https://www.nytimes.com/2021/09/18/us/biden-fda-booster-shot-pfizer.html
0 Comments